Victory Capital Management Inc. Has $10.81 Million Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)

Victory Capital Management Inc. lowered its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 29.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 220,014 shares of the company’s stock after selling 92,035 shares during the quarter. Victory Capital Management Inc. owned about 0.74% of Disc Medicine worth $10,811,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of IRON. Swiss National Bank raised its holdings in Disc Medicine by 50.6% during the first quarter. Swiss National Bank now owns 23,800 shares of the company’s stock valued at $1,482,000 after buying an additional 8,000 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Disc Medicine in the 1st quarter worth approximately $211,000. Vanguard Group Inc. lifted its holdings in Disc Medicine by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 782,751 shares of the company’s stock worth $48,734,000 after purchasing an additional 18,207 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Disc Medicine by 59.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after purchasing an additional 353,382 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Disc Medicine by 17.7% during the first quarter. Janus Henderson Group PLC now owns 521,773 shares of the company’s stock valued at $32,465,000 after purchasing an additional 78,595 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 9,158 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total value of $546,183.12. Following the sale, the insider now directly owns 40,405 shares in the company, valued at $2,409,754.20. This represents a 18.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. In the last three months, insiders sold 16,696 shares of company stock valued at $984,058. Company insiders own 4.24% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of several recent analyst reports. Scotiabank upped their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Jefferies Financial Group assumed coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price for the company. Finally, HC Wainwright raised their target price on Disc Medicine from $70.00 to $118.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Disc Medicine currently has an average rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Trading Up 5.0 %

Shares of IRON stock opened at $62.55 on Thursday. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60. The company has a market capitalization of $1.86 billion, a P/E ratio of -15.72 and a beta of 0.60. The stock has a 50 day moving average of $51.79 and a two-hundred day moving average of $45.73.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. Sell-side analysts predict that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.